US Marijuana Rescheduling Faces Court Challenge Over Regulatory Bypass

On April 28, 2026, the Acting Attorney General of the United States signed a single order that changed the legal status of marijuana in America. The order took effect the same day it was published, without a public comment period, without a congressional vote, and without completing the formal scientific hearing that federal law requires.

Within days, three separate legal challenges were filed in the federal courts. Today, all of them are headed to the United States Court of Appeals for the District of Columbia Circuit, the most powerful federal appeals court in the country for cases involving federal agencies.

One of the challengers is not an anti-marijuana group. It is a pharmaceutical company that has spent nearly a decade and more than ten million dollars trying to turn cannabinoid compounds into real FDA-approved medicine for patients with Huntington's disease, multiple sclerosis, and other serious neurological conditions.

What the Federal Government Actually Did

Here is what the federal government did, and why it matters beyond America's borders:

1. Marijuana was moved to a lower-risk drug category overnight. Under the Controlled Substances Act, drugs are ranked by their risk and medical use. Marijuana was in Schedule I, the most restricted category, alongside heroin. The April 28 order moved it to Schedule III, the same category as ketamine and some anabolic steroids. That sounds like a medical decision. But it was made without the scientific review the law requires.
2. It potentially eliminated a massive tax bill for the marijuana industry. A federal tax rule called Section 280E prevents businesses selling Schedule I or II drugs from deducting normal business expenses. State marijuana dispensaries have paid hundreds of millions of dollars in extra taxes under this rule for years. The moment marijuana moved to Schedule III, that tax burden disappeared. No vote. No hearing. One signature.
3. It created a fast-track registration for state marijuana operators. Any business already licensed by a state to sell marijuana can now get federal DEA registration in as little as six months. MMJ International Holdings has been applying for DEA registration for approximately 2,500 days, nearly seven years, under far stricter pharmaceutical standards. State dispensaries that never went through any of that process now get to cut the line.
4. It was done using a legal shortcut Congress designed for a narrow purpose. The Attorney General used a provision of the law meant to handle scheduling changes required by international treaties. Legal experts, and the government's own Office of Legal Counsel, have acknowledged that this provision has limits. The challengers argue those limits were exceeded.
5. It was done by government agencies that may not have had the authority to do it at all. The Department of Justice has already admitted in a separate federal case, filed by MMJ itself, that the administrative judges used to make DEA drug decisions may be unconstitutional. Those same judges are now scheduled to conduct the next rescheduling hearing on June 29, 2026.

The Patient Safety Question

While the business and legal arguments get most of the attention, there is a patient safety dimension to this story that has been almost entirely ignored.

The April 28 order moved marijuana to Schedule III, a category normally reserved for drugs that have gone through FDA review for safety and effectiveness. But not a single marijuana product sold in state dispensaries has ever been approved by the FDA for any medical condition. The federal government just gave those products a Schedule III classification without the science that Schedule III is supposed to require.

The rescheduling petition filed by MMJ and its co-petitioners makes this argument directly: the government failed to adequately consider the documented health risks of marijuana, including psychosis, impaired brain development in teenagers, addiction, respiratory damage, and cardiovascular harm. The DEA's own scientific review, conducted during the formal hearing process the government terminated, documented those risks extensively. The April 28 order never reconciled them.

A Broad Coalition Challenges the Order

The coalition challenging these federal actions includes:

• Smart Approaches to Marijuana (SAM), a public health organization focused on marijuana safety research and policy advocacy
• Cannabis Industry Victims Educating Litigators (CIVEL), an organization that represents people harmed by the marijuana industry
• New Directions Addiction Recovery Services, a substance abuse recovery clinic serving patients with cannabis use disorder
• Dr. Kenneth Finn and Dr. Elizabeth Stuyt, board-certified physicians with decades of clinical experience treating patients harmed by high-potency marijuana products
• Hillsborough County Anti-Drug Alliance, a local public health coalition
• The National Drug and Alcohol Screening Association, a professional organization representing drug testing and workplace safety programs
• MMJ International Holdings, a pharmaceutical cannabinoid developer pursuing FDA-approved cannabis medicines for serious neurological diseases

The cannabis industry press has called this coalition